JP2024527322A5 - - Google Patents

Info

Publication number
JP2024527322A5
JP2024527322A5 JP2023580691A JP2023580691A JP2024527322A5 JP 2024527322 A5 JP2024527322 A5 JP 2024527322A5 JP 2023580691 A JP2023580691 A JP 2023580691A JP 2023580691 A JP2023580691 A JP 2023580691A JP 2024527322 A5 JP2024527322 A5 JP 2024527322A5
Authority
JP
Japan
Prior art keywords
polynucleotide
pharmaceutical composition
mir
cancer
icd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/036143 external-priority patent/WO2023278897A1/en
Publication of JP2024527322A publication Critical patent/JP2024527322A/ja
Publication of JP2024527322A5 publication Critical patent/JP2024527322A5/ja
Pending legal-status Critical Current

Links

JP2023580691A 2021-07-02 2022-07-05 がんを治療するための組成物および方法 Pending JP2024527322A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163217926P 2021-07-02 2021-07-02
US63/217,926 2021-07-02
US202163218970P 2021-07-07 2021-07-07
US63/218,970 2021-07-07
US202163239372P 2021-08-31 2021-08-31
US63/239,372 2021-08-31
US202263297542P 2022-01-07 2022-01-07
US202263297538P 2022-01-07 2022-01-07
US63/297,542 2022-01-07
US63/297,538 2022-01-07
PCT/US2022/036143 WO2023278897A1 (en) 2021-07-02 2022-07-05 Compositions and methods for treating cancers

Publications (2)

Publication Number Publication Date
JP2024527322A JP2024527322A (ja) 2024-07-24
JP2024527322A5 true JP2024527322A5 (enExample) 2025-07-14

Family

ID=84690676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580691A Pending JP2024527322A (ja) 2021-07-02 2022-07-05 がんを治療するための組成物および方法

Country Status (6)

Country Link
EP (1) EP4362984A1 (enExample)
JP (1) JP2024527322A (enExample)
KR (1) KR20240043747A (enExample)
AU (1) AU2022302143A1 (enExample)
IL (1) IL309662A (enExample)
WO (1) WO2023278897A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2025097000A1 (en) * 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
JP2000507225A (ja) 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US20110184045A1 (en) 2008-06-30 2011-07-28 Gunther Hartmann Silencng and rig-i activation by dual function oligonucleotides
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013064584A1 (en) 2011-10-31 2013-05-10 Riboxx Gmbh Double-stranded RNA for immunostimulation
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2014169049A1 (en) 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
AU2015204446A1 (en) 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
DE102015008536A1 (de) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
LT3386541T (lt) 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
WO2017173427A1 (en) 2016-04-01 2017-10-05 Vycellix Inc Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
US11382966B2 (en) 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
EP3655432A4 (en) 2017-07-17 2021-04-14 Nucleus Therapeutics Pty Ltd BINDING PROTEINS 1
WO2019143297A1 (en) 2018-01-17 2019-07-25 Nanyang Technological University Immunomodulatory small hairpin rna molecules
WO2019152884A1 (en) 2018-02-02 2019-08-08 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
EP3810151B1 (en) 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
EP3990635A1 (en) 2019-06-27 2022-05-04 Rigontec GmbH Design method for optimized rig-i ligands
WO2021042060A1 (en) * 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
EP4045656A1 (en) 2019-10-16 2022-08-24 SomaLogic Operating Co., Inc. Nucleic acid compounds that bind to retinoic acid-inducible gene i protein
CN116529266A (zh) * 2020-08-31 2023-08-01 耶鲁大学 用于将核酸递送到细胞的组合物和方法
AU2021390561A1 (en) * 2020-12-04 2023-06-22 Yale University Compositions and methods for delivery of nucleic acids to cells

Similar Documents

Publication Publication Date Title
JP2024527322A5 (enExample)
US20230303719A1 (en) Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
JP2022533796A5 (enExample)
JP2025507840A5 (enExample)
JP2021516045A (ja) Ｉｌ−１５バリアントおよびその使用
WO2020249003A1 (en) Antibody-interleukin fusion protein and methods of use
US20220273720A1 (en) Lymphodepletion dosing regimens for cellular immunotherapies
JP2024527322A (ja) がんを治療するための組成物および方法
US20250127917A1 (en) Compositions and methods for treating cancers
JP7729561B2 (ja) 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞
CN114685675B (zh) 双特异性抗体及其在治疗癌症中的用途
TW202323295A (zh) 用於產生武裝免疫細胞的方法
CN114621351B (zh) 多特异性抗体及其治疗癌症的用途
CA3226130A1 (en) Compositions and methods for treating cancers
JP2026506647A (ja) 多重特異性γδＴＣＲ抗体を含む組み合わせ療法
JP2025529218A (ja) 養子細胞治療に用いるｂ細胞転座遺伝子１（ｂｔｇ１）の調節
Chen et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy
CN117897178A (zh) 用于治疗癌症的组合物和方法
CN115029318B (zh) 携带多特异性抗体基因的间充质干细胞及其制药用途
CN114716558B (zh) 一种双特异性抗体及其治疗癌症的应用
Babak et al. CAR T Cells for Solid Tumors
CN114716559B (zh) 双特异性抗体及其治疗癌症的应用
WO2026039779A1 (en) Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
CN103980364B (zh) 一种全人源抗her2单克隆抗体及其制备方法与应用
WO2025006794A1 (en) Her-2 -cd3-epsilon bispecific antibodies